ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2026 Earnings Call Transcript May 15, 2026
ARS Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.61 EPS, expectations were $-0.53.
Operator: Good morning, and welcome to ARS Pharmaceuticals First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I will now turn the call over to Justin Chakma, Chief Business Officer. Please go ahead.
Justin Chakma: Good...
